1
|
Zuben de Valega Negrão CV, Cerize NN, Silva Justo-Junior AD, Liszbinski RB, Meneguetti GP, Araujo L, Rocco SA, Almeida Gonçalves KD, Cornejo DR, Leo P, Perecin C, Adamoski D, Gomes Dias SM. HER2 aptamer-conjugated iron oxide nanoparticles with PDMAEMA-b-PMPC coating for breast cancer cell identification. Nanomedicine (Lond) 2024; 19:231-254. [PMID: 38284384 DOI: 10.2217/nnm-2023-0225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2024] Open
Abstract
Aim: To synthesize HER2 aptamer-conjugated iron oxide nanoparticles with a coating of poly(2-(dimethylamino) ethyl methacrylate)-poly(2-methacryloyloxyethylphosphorylcholine) block copolymer (IONPPPs). Methods: Characterization covered molecular structure, chemical composition, thermal stability, magnetic characteristics, aptamer interaction, crystalline nature and microscopic features. Subsequent investigations focused on IONPPPs for in vitro cancer cell identification. Results: Results demonstrated high biocompatibility of the diblock copolymer with no significant toxicity up to 150 μg/ml. The facile coating process yielded the IONPP complex, featuring a 13.27 nm metal core and a 3.10 nm polymer coating. Functionalized with a HER2-targeting DNA aptamer, IONPPP enhanced recognition in HER2-amplified SKBR3 cells via magnetization separation. Conclusion: These findings underscore IONPPP's potential in cancer research and clinical applications, showcasing diagnostic efficacy and HER2 protein targeting in a proof-of-concept approach.
Collapse
Affiliation(s)
- Cyro von Zuben de Valega Negrão
- Graduate Program in Genetics & Molecular Biology, Institute of Biology, University of Campinas (UNICAMP), 13083-864, Campinas, São Paulo, Brazil
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Natália Np Cerize
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Amauri da Silva Justo-Junior
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| | - Raquel Bester Liszbinski
- Graduate Program in Genetics & Molecular Biology, Institute of Biology, University of Campinas (UNICAMP), 13083-864, Campinas, São Paulo, Brazil
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| | - Giovanna Pastore Meneguetti
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Larissa Araujo
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Silvana A Rocco
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| | - Kaliandra de Almeida Gonçalves
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| | - Daniel R Cornejo
- Department of Materials & Mechanics, Institute of Physics, University of São Paulo, 05508-090, São Paulo, São Paulo, Brazil
| | - Patrícia Leo
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Caio Perecin
- Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
| | - Douglas Adamoski
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| | - Sandra M Gomes Dias
- Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
| |
Collapse
|
2
|
Besenhard MO, Pal S, Storozhuk L, Dawes S, Thanh NTK, Norfolk L, Staniland S, Gavriilidis A. A versatile non-fouling multi-step flow reactor platform: demonstration for partial oxidation synthesis of iron oxide nanoparticles. LAB ON A CHIP 2022; 23:115-124. [PMID: 36454245 DOI: 10.1039/d2lc00892k] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
In the last decade flow reactors for material synthesis were firmly established, demonstrating advantageous operating conditions, reproducible and scalable production via continuous operation, as well as high-throughput screening of synthetic conditions. Reactor fouling, however, often restricts flow chemistry and the common fouling prevention via segmented flow comes at the cost of inflexibility. Often, the difficulty of feeding reagents into liquid segments (droplets or slugs) constrains flow syntheses using segmented flow to simple synthetic protocols with a single reagent addition step prior or during segmentation. Hence, the translation of fouling prone syntheses requiring multiple reagent addition steps into flow remains challenging. This work presents a modular flow reactor platform overcoming this bottleneck by fully exploiting the potential of three-phase (gas-liquid-liquid) segmented flow to supply reagents after segmentation, hence facilitating fouling free multi-step flow syntheses. The reactor design and materials selection address the operation challenges inherent to gas-liquid-liquid flow and reagent addition into segments allowing for a wide range of flow rates, flow ratios, temperatures, and use of continuous phases (no perfluorinated solvents needed). This "Lego®-like" reactor platform comprises elements for three-phase segmentation and sequential reagent addition into fluid segments, as well as temperature-controlled residence time modules that offer the flexibility required to translate even complex nanomaterial synthesis protocols to flow. To demonstrate the platform's versatility, we chose a fouling prone multi-step synthesis, i.e., a water-based partial oxidation synthesis of iron oxide nanoparticles. This synthesis required I) the precipitation of ferrous hydroxides, II) the addition of an oxidation agent, III) a temperature treatment to initiate magnetite/maghemite formation, and IV) the addition of citric acid to increase the colloidal stability. The platform facilitated the synthesis of colloidally stable magnetic nanoparticles reproducibly at well-controlled synthetic conditions and prevented fouling using heptane as continuous phase. The biocompatible particles showed excellent heating abilities in alternating magnetic fields (ILP values >3 nH m2 kgFe-1), hence, their potential for magnetic hyperthermia cancer treatment. The platform allowed for long term operation, as well as screening of synthetic conditions to tune particle properties. This was demonstrated via the addition of tetraethylenepentamine, confirming its potential to control particle morphology. Such a versatile reactor platform makes it possible to translate even complex syntheses into flow, opening up new opportunities for material synthesis.
Collapse
Affiliation(s)
- Maximilian O Besenhard
- Department of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK.
| | - Sayan Pal
- Department of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK.
| | - Liudmyla Storozhuk
- Biophysics Group, Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, UK
| | - Simon Dawes
- Department of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK.
| | - Nguyen Thi Kim Thanh
- Biophysics Group, Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, UK
- UCL Healthcare Biomagnetics and Nanomaterials Laboratories, University College London, 21 Albemarle Street, London W1S 4BS, UK
| | - Laura Norfolk
- Department of Chemistry, The University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK
| | - Sarah Staniland
- Department of Chemistry, The University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK
| | - Asterios Gavriilidis
- Department of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK.
| |
Collapse
|
3
|
Novel Magnetic Elastic Phase-Change Nanodroplets as Dual Mode Contrast Agent for Ultrasound and Magnetic Resonance Imaging. Polymers (Basel) 2022; 14:polym14142915. [PMID: 35890691 PMCID: PMC9318938 DOI: 10.3390/polym14142915] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 06/05/2022] [Accepted: 06/08/2022] [Indexed: 01/25/2023] Open
Abstract
Recently, dual-mode imaging systems merging magnetic resonance imaging (MRI) and ultrasound (US) have been developed. Designing a dual-mode contrast agent is complex due to different mechanisms of enhancement. Herein, we describe novel phase change nanodroplets (PCNDs) with perfluoropentane encapsulated in a pre-polyglycerol sebacate (pre-PGS) shell loaded with polyethylene glycol (PEG)-coated iron oxide nanoparticles as having a dual-mode contrast agent effect. Iron oxide nanoparticles were prepared via the chemical co-precipitation method and PCNDs were prepared via the solvent displacement technique. PCNDs showed excellent enhancement in the in vitro US much more than Sonovue® microbubbles. Furthermore, they caused a susceptibility effect resulting in a reduction of signal intensity on MRI. An increase in the concentration of nanoparticles caused an increase in the MR contrast effect but a reduction in US intensity. The concentration of nanoparticles in a shell of PCNDs was optimized to obtain a dual-mode contrast effect. Biocompatibility, hemocompatibility, and immunogenicity assays showed that PCNDs were safe and non-immunogenic. Another finding was the dual-mode potential of unloaded PCNDs as T1 MR and US contrast agents. Results suggest the excellent potential of these PCNDs for use as dual-mode contrast agents for both MRI and US.
Collapse
|
4
|
Włodarczyk A, Gorgoń S, Radoń A, Bajdak-Rusinek K. Magnetite Nanoparticles in Magnetic Hyperthermia and Cancer Therapies: Challenges and Perspectives. NANOMATERIALS 2022; 12:nano12111807. [PMID: 35683663 PMCID: PMC9182445 DOI: 10.3390/nano12111807] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 05/23/2022] [Accepted: 05/23/2022] [Indexed: 12/12/2022]
Abstract
Until now, strategies used to treat cancer are imperfect, and this generates the need to search for better and safer solutions. The biggest issue is the lack of selective interaction with neoplastic cells, which is associated with occurrence of side effects and significantly reduces the effectiveness of therapies. The use of nanoparticles in cancer can counteract these problems. One of the most promising nanoparticles is magnetite. Implementation of this nanoparticle can improve various treatment methods such as hyperthermia, targeted drug delivery, cancer genotherapy, and protein therapy. In the first case, its feature makes magnetite useful in magnetic hyperthermia. Interaction of magnetite with the altered magnetic field generates heat. This process results in raised temperature only in a desired part of a patient body. In other therapies, magnetite-based nanoparticles could serve as a carrier for various types of therapeutic load. The magnetic field would direct the drug-related magnetite nanoparticles to the pathological site. Therefore, this material can be used in protein and gene therapy or drug delivery. Since the magnetite nanoparticle can be used in various types of cancer treatment, they are extensively studied. Herein, we summarize the latest finding on the applicability of the magnetite nanoparticles, also addressing the most critical problems faced by smart nanomedicine in oncological therapies.
Collapse
Affiliation(s)
- Agnieszka Włodarczyk
- Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland;
| | - Szymon Gorgoń
- Department of Surgical and Perioperative Sciences, Surgery, Umeå University, 901 87 Umeå, Sweden;
| | - Adrian Radoń
- Łukasiewicz Research Network—Institute of Non-Ferrous Metals, Sowinskiego 5 St., 44-100 Gliwice, Poland;
| | - Karolina Bajdak-Rusinek
- Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland;
- Correspondence: ; Tel.: +48-32-208-8382
| |
Collapse
|
5
|
Hernández-Guerrero N, Castro-Longoria E, Torres-Gómez N, Ruiz VF, Arenas-Alatorre J, Martínez-Mondragón MM, Vilchis-Nestor AR. Magnetite/Rhodamine 6G nanoparticles internalization in Neurospora crassa cells: towards the magnetic hyperthermia application. APPLIED NANOSCIENCE 2022. [DOI: 10.1007/s13204-021-02317-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|